Czira, A. ., Banks, V. ., Requena, G. ., Wood, R. ., Tritton, T. ., Wild, R. ., … Ismaila, A. . (2024). Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B(2)-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study. BMJ Open, 14, e072361. http://doi.org/10.1136/bmjopen-2023-072361
Adrenergic beta-2 Receptor Agonists/therapeutic use
Suissa, S. ., Dell’Aniello, S. ., & Ernst, P. . (2022). Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. Copd, 19, 133–141. http://doi.org/10.1080/15412555.2022.2045265
Suissa, S. ., Dell’Aniello, S. ., & Ernst, P. . (2022). Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. Copd, 19, 109–117. http://doi.org/10.1080/15412555.2022.2035705